Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 180

1.

Relation Between F-18 FDG Uptake of PET/CT and BRAFV600E Mutation in Papillary Thyroid Cancer.

Yoon S, An YS, Lee SJ, So EY, Kim JH, Chung YS, Yoon JK.

Medicine (Baltimore). 2015 Dec;94(48):e2063. doi: 10.1097/MD.0000000000002063.

2.

Relationship Between 18F-fluorodeoxyglucose Accumulation and the BRAF V600E Mutation in Papillary Thyroid Cancer.

Chang JW, Park KW, Heo JH, Jung SN, Liu L, Kim SM, Kwon IS, Koo BS.

World J Surg. 2018 Jan;42(1):114-122. doi: 10.1007/s00268-017-4136-y.

PMID:
28808756
3.

Relationships between transporter expression and the status of BRAF V600E mutation and F-18 FDG uptake in papillary thyroid carcinomas.

Yoon M, Jung SJ, Kim TH, Ha TK, Urm SH, Park JS, Lee SM, Bae SK.

Endocr Res. 2016;41(1):64-9. doi: 10.3109/07435800.2015.1066803. Epub 2015 Oct 29.

PMID:
26513490
4.

Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.

Choi EK, Chong A, Ha JM, Jung CK, O JH, Kim SH.

Clin Endocrinol (Oxf). 2017 Jul;87(1):73-79. doi: 10.1111/cen.13335. Epub 2017 Apr 18.

PMID:
28329426
5.

Correlation of BRAFV600E Mutation and Glucose Metabolism in Thyroid Cancer Patients: An ¹⁸F-FDG PET Study.

Nagarajah J, Ho AL, Tuttle RM, Weber WA, Grewal RK.

J Nucl Med. 2015 May;56(5):662-7. doi: 10.2967/jnumed.114.150607. Epub 2015 Mar 26.

6.

Clinical value of visually identifiable 18F-fluorodeoxyglucose uptake in primary papillary thyroid microcarcinoma.

Hwang SO, Lee SW, Kang JK, Choi HH, Kim WW, Park HY, Jung JH.

Otolaryngol Head Neck Surg. 2014 Sep;151(3):415-20. doi: 10.1177/0194599814537224. Epub 2014 Jun 5.

PMID:
24903453
7.

Correlation of BRAF mutation and SUVmax levels in thyroid cancer patients incidentally detected in 18F-fluorodeoxyglucose positron emission tomography.

Ozderya A, Temizkan S, Gul AE, Ozugur S, Sargin M, Aydin K.

Endocrine. 2017 Jan;55(1):215-222. doi: 10.1007/s12020-016-1128-x. Epub 2016 Oct 1.

PMID:
27696232
8.

Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.

Kang JH, Jung DW, Pak KJ, Kim IJ, Kim HJ, Cho JK, Shin SC, Wang SG, Lee BJ.

Head Neck. 2018 Jan;40(1):94-102. doi: 10.1002/hed.24967. Epub 2017 Nov 11.

PMID:
29130586
9.

Non-FDG-avid primary papillary thyroid carcinoma may not differ from FDG-avid papillary thyroid carcinoma.

Kim MH, Ko SH, Bae JS, Lee SH, Jung CK, Lim DJ, Baek KH, Kim SH, Lee JM, Kang MI, Cha BY.

Thyroid. 2013 Nov;23(11):1452-60. doi: 10.1089/thy.2013.0051. Epub 2013 Sep 19.

PMID:
23688271
10.

Analysis of predictability of F-18 fluorodeoxyglucose-PET/CT in the recurrence of papillary thyroid carcinoma.

Kim SK, So Y, Chung HW, Yoo YB, Park KS, Hwang TS, Kim B, Lee WW.

Cancer Med. 2016 Oct;5(10):2756-2762. doi: 10.1002/cam4.867. Epub 2016 Aug 19.

11.

Feasibility of FDG-PET/CT for the initial diagnosis of papillary thyroid cancer.

Kim H, Na KJ, Choi JH, Ahn BC, Ahn D, Sohn JH.

Eur Arch Otorhinolaryngol. 2016 Jun;273(6):1569-76. doi: 10.1007/s00405-015-3640-7. Epub 2015 May 14.

PMID:
25971994
12.

Prevalence and significance of thyroid uptake detected by ¹⁸F-FDG PET.

Ho TY, Liou MJ, Lin KJ, Yen TC.

Endocrine. 2011 Oct;40(2):297-302. doi: 10.1007/s12020-011-9470-5. Epub 2011 Apr 20. Erratum in: Endocrine. 2011 Oct;40(2):303.

PMID:
21505891
13.

PROGNOSTIC VALUE OF LYMPH NODE UPTAKE ON PRETREATMENT F-18 FDG PET/CT IN PATIENTS WITH N1B PAPILLARY THYROID CARCINOMA.

Lee CH, Lee SW, Son SH, Hong CM, Jeong JH, Jeong SY, Ahn BC, Lee J.

Endocr Pract. 2019 Aug;25(8):787-793. doi: 10.4158/EP-2018-0607. Epub 2019 Apr 23.

PMID:
31013158
14.

THE RELATIONSHIP OF BRAFV600E MUTATION STATUS TO FDG PET/CT AVIDITY IN THYROID CANCER: A REVIEW AND META-ANALYSIS.

Santhanam P, Khthir R, Solnes LB, Ladenson PW.

Endocr Pract. 2018 Jan;24(1):21-26. doi: 10.4158/EP-2017-0080. Epub 2017 Nov 16. Review.

PMID:
29144823
15.

Real-Time PCR Cycle Threshold Values for the BRAFV600E Mutation in Papillary Thyroid Microcarcinoma May Be Associated With Central Lymph Node Metastasis: A Retrospective Study.

Park VY, Kim EK, Lee HS, Moon HJ, Yoon JH, Kwak JY.

Medicine (Baltimore). 2015 Jul;94(28):e1149. doi: 10.1097/MD.0000000000001149.

16.

Factors associated with positive F-18 flurodeoxyglucose positron emission tomography before thyroidectomy in patients with papillary thyroid carcinoma.

Kim BS, Kim SJ, Kim IJ, Pak K, Kim K.

Thyroid. 2012 Jul;22(7):725-9. doi: 10.1089/thy.2011.0031. Epub 2012 Apr 23.

17.

BRAF in primary and recurrent papillary thyroid cancers: the relationship with (131)I and 2-[(18)F]fluoro-2-deoxy-D-glucose uptake ability.

Barollo S, Pennelli G, Vianello F, Watutantrige Fernando S, Negro I, Merante Boschin I, Pelizzo MR, Rugge M, Mantero F, Nacamulli D, Girelli ME, Busnardo B, Mian C.

Eur J Endocrinol. 2010 Oct;163(4):659-63. doi: 10.1530/EJE-10-0290. Epub 2010 Jul 20.

PMID:
20647301
18.

The role of BRAFV600E mutation and ultrasonography for the surgical management of a thyroid nodule suspicious for papillary thyroid carcinoma on cytology.

Moon HJ, Kwak JY, Kim EK, Choi JR, Hong SW, Kim MJ, Son EJ.

Ann Surg Oncol. 2009 Nov;16(11):3125-31. doi: 10.1245/s10434-009-0644-9. Epub 2009 Jul 31.

PMID:
19644722
19.

The thyroid imaging reporting and data system on US, but not the BRAFV600E mutation in fine-needle aspirates, is associated with lateral lymph node metastasis in PTC.

Park VY, Kim EK, Moon HJ, Yoon JH, Kwak JY.

Medicine (Baltimore). 2016 Jul;95(29):e4292. doi: 10.1097/MD.0000000000004292.

20.

Associations of the BRAF(V600E) mutation with sonographic features and clinicopathologic characteristics in a large population with conventional papillary thyroid carcinoma.

Park AY, Son EJ, Kim JA, Youk JH, Park YJ, Park CS, Chang HS.

PLoS One. 2014 Oct 22;9(10):e110868. doi: 10.1371/journal.pone.0110868. eCollection 2014.

Supplemental Content

Support Center